Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group

J Verweij; P H de Mulder; A de Graeff; J B Vermorken; J Wildiers; J Kerger; J Schornagel; F Cognetti; A Kirkpatrick; T Sahmoud; J L Lefebvre

Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group

J Verweij, P H de Mulder, A de Graeff, J B Vermorken, J Wildiers, J Kerger, J Schornagel, F Cognetti, A Kirkpatrick, T Sahmoud, J L Lefebvre

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BACKGROUND: Based on activity in a case report, mitoxantrone was studied in a phase II study in adenoid cystic carcinoma.

PATIENTS AND METHODS: Patients with symptomatic and/or rapidly progressive metastatic or recurrent adenoid cystic carcinoma were eligible for this study. They were treated with mitoxantrone given intravenously by bolus injection at a dose of 14 mg/m2, cycles repeated every 3 weeks.

RESULTS: Thirty-six chemotherapy-naive patients entered on trial, 4 were ineligible. A median of 6 cycles per patient were given. Leucocytopenia (in 97% of patients) was the most important side effect and tended to be cumulative. Other side effects were mainly mild to moderate and consisted of nausea (62%), vomiting (29%), alopecia (53%) and mucositis (41%). Four of 32 patients had a partial response (12%; 95% CI 4%-29%) lasting 3-13 months, 22 patients (69%) had a stable disease.

CONCLUSION: Mitoxantrone at this dose and schedule has modest activity in adenoid cystic carcinomas.

Original language	English
Pages (from-to)	867-9
Number of pages	3
Journal	Annals of Oncology
Volume	7
Issue number	8
Publication status	Published - 1996

Keywords

Adult
Aged
Antineoplastic Agents
Carcinoma, Adenoid Cystic
Confidence Intervals
Disease-Free Survival
Dose-Response Relationship, Drug
Female
Head and Neck Neoplasms
Humans
Infusions, Intravenous
Male
Middle Aged
Mitoxantrone
Prognosis

Cite this

@article{688db36e87f54bb9a8e0107d8064b3c2,

title = "Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group",

abstract = "BACKGROUND: Based on activity in a case report, mitoxantrone was studied in a phase II study in adenoid cystic carcinoma.PATIENTS AND METHODS: Patients with symptomatic and/or rapidly progressive metastatic or recurrent adenoid cystic carcinoma were eligible for this study. They were treated with mitoxantrone given intravenously by bolus injection at a dose of 14 mg/m2, cycles repeated every 3 weeks.RESULTS: Thirty-six chemotherapy-naive patients entered on trial, 4 were ineligible. A median of 6 cycles per patient were given. Leucocytopenia (in 97% of patients) was the most important side effect and tended to be cumulative. Other side effects were mainly mild to moderate and consisted of nausea (62%), vomiting (29%), alopecia (53%) and mucositis (41%). Four of 32 patients had a partial response (12%; 95% CI 4%-29%) lasting 3-13 months, 22 patients (69%) had a stable disease.CONCLUSION: Mitoxantrone at this dose and schedule has modest activity in adenoid cystic carcinomas.",

keywords = "Adult, Aged, Antineoplastic Agents, Carcinoma, Adenoid Cystic, Confidence Intervals, Disease-Free Survival, Dose-Response Relationship, Drug, Female, Head and Neck Neoplasms, Humans, Infusions, Intravenous, Male, Middle Aged, Mitoxantrone, Prognosis",

author = "J Verweij and {de Mulder}, {P H} and {de Graeff}, A and Vermorken, {J B} and J Wildiers and J Kerger and J Schornagel and F Cognetti and A Kirkpatrick and T Sahmoud and Lefebvre, {J L}",

year = "1996",

language = "English",

volume = "7",

pages = "867--9",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "8",

}

TY - JOUR

T1 - Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group

AU - Verweij, J

AU - de Mulder, P H

AU - de Graeff, A

AU - Vermorken, J B

AU - Wildiers, J

AU - Kerger, J

AU - Schornagel, J

AU - Cognetti, F

AU - Kirkpatrick, A

AU - Sahmoud, T

AU - Lefebvre, J L

PY - 1996

Y1 - 1996

N2 - BACKGROUND: Based on activity in a case report, mitoxantrone was studied in a phase II study in adenoid cystic carcinoma.PATIENTS AND METHODS: Patients with symptomatic and/or rapidly progressive metastatic or recurrent adenoid cystic carcinoma were eligible for this study. They were treated with mitoxantrone given intravenously by bolus injection at a dose of 14 mg/m2, cycles repeated every 3 weeks.RESULTS: Thirty-six chemotherapy-naive patients entered on trial, 4 were ineligible. A median of 6 cycles per patient were given. Leucocytopenia (in 97% of patients) was the most important side effect and tended to be cumulative. Other side effects were mainly mild to moderate and consisted of nausea (62%), vomiting (29%), alopecia (53%) and mucositis (41%). Four of 32 patients had a partial response (12%; 95% CI 4%-29%) lasting 3-13 months, 22 patients (69%) had a stable disease.CONCLUSION: Mitoxantrone at this dose and schedule has modest activity in adenoid cystic carcinomas.

AB - BACKGROUND: Based on activity in a case report, mitoxantrone was studied in a phase II study in adenoid cystic carcinoma.PATIENTS AND METHODS: Patients with symptomatic and/or rapidly progressive metastatic or recurrent adenoid cystic carcinoma were eligible for this study. They were treated with mitoxantrone given intravenously by bolus injection at a dose of 14 mg/m2, cycles repeated every 3 weeks.RESULTS: Thirty-six chemotherapy-naive patients entered on trial, 4 were ineligible. A median of 6 cycles per patient were given. Leucocytopenia (in 97% of patients) was the most important side effect and tended to be cumulative. Other side effects were mainly mild to moderate and consisted of nausea (62%), vomiting (29%), alopecia (53%) and mucositis (41%). Four of 32 patients had a partial response (12%; 95% CI 4%-29%) lasting 3-13 months, 22 patients (69%) had a stable disease.CONCLUSION: Mitoxantrone at this dose and schedule has modest activity in adenoid cystic carcinomas.

KW - Adult

KW - Aged

KW - Antineoplastic Agents

KW - Carcinoma, Adenoid Cystic

KW - Confidence Intervals

KW - Disease-Free Survival

KW - Dose-Response Relationship, Drug

KW - Female

KW - Head and Neck Neoplasms

KW - Humans

KW - Infusions, Intravenous

KW - Male

KW - Middle Aged

KW - Mitoxantrone

KW - Prognosis

M3 - Article

C2 - 8922205

SN - 0923-7534

VL - 7

SP - 867

EP - 869

JO - Annals of Oncology

JF - Annals of Oncology

IS - 8

ER -

Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group

Abstract

Keywords

Fingerprint

Cite this